Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan
Japanese Journal of Clinical Oncology · 06.04.2025 · 55 (4) · 383-390
DOI: 10.1093/jjco/hyae175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 20.12.2024. Verfasst von Hidehito Horinouchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.
Abstract (Originalsprache)
Objective
To describe standard of care and inform the evolving unmet need among extensive stage small-cell lung cancer (ES-SCLC) patients in Japan since approval of first-line anti-PD-L1 therapies, we describe treatment patterns and overall survival by line of therapy.
Methods
We conducted a descriptive analysis of adult ES-SCLC patients in Japan using de-identified patient data within the MDV database (hospital-based claims) to describe treatment patterns and DeSC database (payer-based claims linked to mortality of municipality records) to describe both treatment patterns and real-world overall survival (rwOS).
Results
The study population of MDV and DeSC cohorts included 6302 and 903 patients, respectively. First-line anti-PD-L1 therapy-based regimens grew since their approval in 2019 and were used in ~35% and ~59% of patients in 2022, in the MDV and DeSC cohorts, respectively. Amrubicin monotherapy was the most common second-line (2 L) regimen before and after 1 L anti-PD-L1 approvals. No clear standard of care was identified in third-line (3 L) and fourth-line (4 L). Median rwOS following 1 L therapy was 10.6 months (95% CI: 9.0, 11.8) and 9.3 months (95% CI: 8.3, 10.3) in patients who did and did not receive anti-PD-L1 therapy, respectively. Following 2 L, 3 L, and 4 L therapy, median rwOS was 6.7 months (95% CI: 5.9, 7.4), 5.5 months (95% CI: 4.4, 6.4), and 4.7 months (95% CI: 3.4, 6.9), respectively.
Conclusions
Anti-PD-L1 therapies have become part of first-line standard of care but survival in treated Japanese ES-SCLC patients remains poor, highlighting the unmet medical need in the post anti-PD-L1 era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Center for Observational Research, Amgen K.K., 9-7-1 Akasaka, Minato-ku, Tokyo 107-6239, Japan.
- Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, United States.
- Center for Observational Research, Amgen Ltd., 4 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom.
ORCID-Profile: Hidehito Horinouchi, Chia-Hsien Suzu Chang
Förderung
- Amgen Inc
Zitieren
APA
Horinouchi, H., Chang, C. S., Shaw, J., Archangelidi, O., Balasubramanian, A., & Pundole, X. (2025). Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan. Japanese Journal of Clinical Oncology, 55(4), 383-390. https://doi.org/10.1093/jjco/hyae175
Vancouver
Horinouchi H, Chang CS, Shaw J, Archangelidi O, Balasubramanian A, Pundole X. Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan. Japanese Journal of Clinical Oncology. 2025;55(4):383-390. doi:10.1093/jjco/hyae175
BibTeX
@article{Horinouchi2025,
author = {Horinouchi, Hidehito and Chang, Chia-Hsien Suzu and Shaw, Jaime and Archangelidi, Olga and Balasubramanian, Akhila and Pundole, Xerxes},
title = {Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
volume = {55},
number = {4},
pages = {383--390},
doi = {10.1093/jjco/hyae175}
}
EUVIMED